John C

No ORCID on file · 1 paper in corpus

2025

Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer.

Frontiers in pharmacology ·doi:10.3389/fphar.2025.1520771

ObjectiveChronic inflammation is a key contributor to carcinogenesis, progression, and chemoresistance in ovarian cancer, making inflammatory pathways a logical therapeutic target for the treatment of this disease. Sulindac, a commonly used…